Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Metabolic
A synthetic dual incretin receptor agonist peptide studied in metabolic research models.
Reviewed by Dr. James Whitfield, PharmD · Published · Last reviewed · For research use only.
Type
Synthetic peptide (acylated, 39 residues)
Molecular formula
C225H348N48O68
Molecular weight
~4,810.5 g/mol
CAS number
2023788-19-2
Amino acids
39
Fatty acid chain
C20 diacid
Modification
Aib at positions 2 and 13; Lys20 acylated with a C20 fatty-diacid via a spacer linker; modifications confer protease resistance and albumin binding.
LUV TRZ is a synthetic peptide agonist at two class B1 GPCRs — the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R) — with preferential activity at GIPR relative to GLP-1R. Signaling studies indicate that at GLP-1R the compound favors Gαs–cAMP signaling over β-arrestin recruitment, with differential receptor internalization relative to native GLP-1; at GIPR it preferentially activates Gαs–cAMP signaling. Two Aib residues at positions 2 and 13 confer protease resistance; the C20 fatty-diacid chain on Lys20, attached via a spacer, promotes reversible albumin binding and extends the peptide's circulating half-life.
Lyophilized
20°C (-80°C long term)
lyophilized powder stable ~3 years.
Prepare stock solutions fresh; protect from light; keep sealed and dry.
Reviews
Galindo RJ, et al. (2025). Diabetes Therapy — Narrative review examining LUV TRZ pharmacology and mechanism
Zhou Q, et al. (2023). Diabetology & Metabolic Syndrome — Systematic review of clinical trial designs examining LUV TRZ; cited for study-design context
Min T, et al. (2021). Diabetes Ther — Review of SURPASS clinical trial program design and dual-agonist pharmacology
Reviews
Forzano I, et al. (2022). Int J Mol Sci — Systematic narrative review of dual GIP/GLP-1 receptor agonist pharmacology and clinical study data
Tang Y, et al. (2022). Front Pharmacol — Systematic review and meta-analysis of randomised trials evaluating a dual incretin agonist; cited for study-design context
Lin F, et al. (2023). PLoS One — Systematic review of randomised trials examining dual incretin agonist metabolic endpoints and safety profile
Clinical
Thomas MK, et al. (2021). J Clin Endocrinol Metab — Phase 3 substudy assessing pancreatic beta-cell markers and insulin sensitivity indices in a dual-agonist clinical trial
Rosenstock J, et al. (2021). Lancet — Randomized clinical study (SURPASS-1); cited for study-design context
Frías JP, et al. (2021). N Engl J Med — Randomized clinical study (SURPASS-2); cited for study-design context
Ludvik B, et al. (2021). Lancet — Randomized clinical study (SURPASS-3); cited for study-design context
Heise T, et al. (2022). Lancet Diabetes Endocrinol — Multicentre phase 1 trial examining pancreatic islet function and insulin sensitivity with a dual incretin agonist versus placebo or GLP-1R agonist
Jastreboff AM, et al. (2022). N Engl J Med — Randomized clinical study (SURMOUNT-1); cited for study-design context
Loomba R, et al. (2024). N Engl J Med — Randomized clinical study (SYNERGY-NASH); cited for study-design context
Malhotra A, et al. (2024). N Engl J Med — Randomized clinical study (SURMOUNT-OSA); cited for study-design context
Packer M, et al. (2025). N Engl J Med — Randomized clinical study (SUMMIT); cited for study-design context
Primary research
Rees TA, et al. (2024). Frontiers in Pharmacology — Signaling assay examining LUV TRZ activity at GIPR polymorphic variants
Zhao F, et al. (2022). Nature Communications — Cryo-EM structural study of LUV TRZ bound to GIPR and GLP-1R complexes
Sun W, et al. (2022). Proceedings of the National Academy of Sciences — Cryo-EM structural characterization of a dual incretin receptor agonist–receptor complex
Willard FS, et al. (2020). JCI Insight — Investigation of GIPR and GLP-1R signaling pathway selectivity and bias
Coskun T, et al. (2018). Molecular Metabolism — Preclinical characterization and Phase 1 study design for LUV TRZ; cited for study-design context
El K, et al. (2023). Nat Metab — Ex vivo human islet assay examining GIPR dependence of incretin co-agonist hormone secretion
Research Use Only
These products are intended for research purposes only and are not for human consumption. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease.
| Compound | Type | Molecular weight | CAS number |
|---|---|---|---|
| LUV TRZThis page | Synthetic peptide (acylated, 39 residues) | ~4,810.5 g/mol | 2023788-19-2 |
| LUV RT | Synthetic peptide (acylated, 39 residues) | ~4,731 Da | 2381089-83-2 |
| LUV SM | Synthetic peptide (acylated, 31 residues) | ~4,114 g/mol | 910463-68-2 |
| LUV TRZ2 | Synthetic linear peptide (dual GLP-1R/GIPR agonist; acylated, 39 residues) | ~4,814 g/mol | 2023788-19-2 |
| AOD-9604 | Synthetic peptide (cyclic, 16 residues) | ~1,815 g/mol | 221231-10-3 |
Comparison of laboratory reference specifications only. For research use only; not a therapeutic comparison.
Quality & methods